In vitro characterization of two novel biodegradable vectors for the delivery of radiolabeled antisense oligonucleotides. (scientific article published on December 2010)

Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494.

Q33832087

Cellular delivery of antisense oligonucleotides

Q33935283

Use of positron emission tomography in animal research

Q34282856

Vehicles for oligonucleotide delivery to tumours

Q34518719

Labelled oligonucleotides as radiopharmaceuticals: pitfalls, problems and perspectives.

Q34673888

Prospects for cationic polymers in gene and oligonucleotide therapy against cancer

Q34804863

In vivo imaging with oligonucleotides for diagnosis and drug development

Q35127223

Antisense targeting in cell culture with radiolabeled DNAs--a brief review of recent progress

Q35907491

Intracellular trafficking of nonviral vectors

Q36218205

Progress in developing cationic vectors for non-viral systemic gene therapy against cancer

Q37171355

Evidence for the role of proteoglycans in cation-mediated gene transfer

Q37236667

Biological barriers to therapy with antisense and siRNA oligonucleotides

Q37378340

Radiolabelled oligonucleotides for imaging of gene expression with PET.

Q37616198

The role and future potential of fluorinated biomarkers in positron emission tomography

Q38028536

Persistent p21Cip1 induction mediates G(1) cell cycle arrest by methylseleninic acid in DU145 prostate cancer cells.

Q39718536

Estrogen regulated expression of the p21 Waf1/Cip1 gene in estrogen receptor positive human breast cancer cells

Q39725747

Involvement of p21Waf1/Cip1 cleavage during roscovitine-induced apoptosis in non-small cell lung cancer cells.

Q39767769

Biodegradable amphiphilic poly(ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarriers for efficient siRNA delivery

Q39932073

Induction of accelerated senescence by gamma radiation in human solid tumor-derived cell lines expressing wild-type TP53.

Q40479643

In vitro detection of mdr1 mRNA in murine leukemia cells with 111In-labeled oligonucleotide.

Q40479918

Patterns of intracellular compartmentalization, trafficking and acidification of 5'-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells

Q40522457

Antisense imaging of epidermal growth factor-induced p21(WAF-1/CIP-1) gene expression in MDA-MB-468 human breast cancer xenografts.

Q40663491

Automated synthesis of an 18F-labelled pyridine-based alkylating agent for high yield oligonucleotide conjugation.

Q42209635

Labeling of an antisense oligonucleotide with [(18)F]FPy5yne

Q43150247

Evaluation of fluorine-18-labeled alkylating agents as potential synthons for the labeling of oligonucleotides

Q44388528

Design and synthesis of a new [18F]fluoropyridine-based haloacetamide reagent for the labeling of oligonucleotides: 2-bromo-N-[3-(2-[18F]fluoropyridin-3-yloxy)propyl]acetamide.

Q44900275

p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis

Q73453117

General method to label antisense oligonucleotides with radioactive halogens for pharmacological and imaging studies

Q74337134

First "antisense" drug will treat CMV retinitis

Q77308365

P433

issue

P921

main subject

biodegradation